Moderna, a US pharmaceutical company, has halted plans to build a vaccine manufacturing facility in Kenya due to over $1 billion in losses from decreased demand for COVID-19 vaccines in Africa.
The decision comes after facing over $1 billion in losses and cancelled orders since 2022. Moderna aims to align its investments with changing healthcare needs on the continent.
Initially, the plan was to produce 500 million vaccine doses annually, focusing on drug substance manufacturing. This delay raises concerns about vaccine access in Kenya and Africa, especially as the country aims to combat COVID-19.
